Hello, everybody, and welcome to this webcast in relation to our quarterly report for the third quarter of 2024. Xbrane Biopharma AB, I am Martin Åmark, the CEO, and I have with me Anette Lindqvist, our CFO. In this call. We will, as usual, go through the operational and financial highlights of the quarter. And then we will open up for questions both via audio as well as on the chat.
Um, so let's start here. Most of you who are calling in are probably aware of our business model; we are engaged in the development of biosimilars. We have a portfolio that consists of four biosimilars and biosimilar candidates under development. All in all, addressing reference product sales expected to reach about €26 billion by 2026. Our first program, Ximluci, was launched. Similar to the eye drug Lucentis, Ximluci® was approved in Europe and launched there in March 2023 by our partner Stada, and is currently undergoing the regulatory process for approval in the US. Post-approval, it is set to be launched by our US partner, Valarum Biologics. We have, then, two programs: Cimzia® and Opdivo® biosimilar candidates, respectively, that are in a late preclinical stage. We have successfully scaled up the respective production processes and demonstrated comparative analytical similarity to the respective reference products, and we are ready to take the programs into clinical trials during the course of next year. And for these two programs, we're also running very active out-licensing processes with the ambition to identify and tie up a commercialization partner that can also co-fund a significant portion of the continued development of these biosimilar candidates up until they reach the approval stage in Europe and the US. Then we have early stage development of a biosimilar candidate to Darzalex. But we'll start off with Ximluci. This is a snapshot of where we, together with Stada, are from a commercialization perspective, across Europe and the Middle East. We are continuing to see solid volume growth. We had a volume growth of about 23% in Q3 versus Q2 this year, indicating that units were sold to end customers. Despite that, we saw a more or less stable net sales level, which was due to a slightly negative mix effect. This effect essentially reflects the relative volumes coming from different regions with slightly different pricing. And that is most likely going to vary a little bit from quarter to quarter as we continue this journey. But I think the important thing here is that we are continuing to see the strong volume growth trend, and we're very pleased with that. And, Stada is making good progress across a multitude of different countries where the product is launched in Europe. Overall, then, we estimate that Ximluci has a value market share of a little bit above 1% in a market of about €1.2 billion. And that is considering the annual net sales of the originator product, Lucentis, and Lucentis biosimilars on the market in this region. And we're happy to see also that Ximluci is number two from a market share perspective among the different ranibizumab biosimilars in this region. So I think the continued development is going according to plan when it comes to the ongoing commercialization efforts of Ximluci in Europe. We have also started to see approvals in some countries outside of Europe. We've seen approvals in Bahrain, UAE, Uzbekistan, and Switzerland in the recent past. And we are expecting to see launches across these countries in the near term future, along with more approvals and additional countries, particularly in the Middle East region where we have ongoing regulatory processes. Um, and we are working according to the previously communicated plan, to resubmit the BLA to the FDA in the fourth quarter of this year. Um, so for those of you who have followed us, we received a complete response letter on our initial BLA or, that is to say, Biologics License Application to the FDA for Ximluci. We received a complete response letter in April, and we have since then worked through the deficiencies stated by the FDA. Stated in the complete response letter. And that entailed, on the one hand, the qualification of a new reference standard. Since the FDA wanted to see a slightly stricter band for one specific analytical method on the reference standard to be used for releasing the product in the US. So that is going according to plan. And we're also collaborating with our respective contract manufacturers to address certain observations and deficiencies identified by the FDA in the pre-approval inspections that occurred as part of the original procedure. And it's a six-month review process for a resubmitted BLA. Hence, we are expecting to have a new, so-called data decision date in Q2 next year, and we then hope for an approval and that we can subsequently move towards supporting our US partner, Biogen Inc., for the launch of the product in the US. Um, we're also working together with Strada on prefilled syringes. Um, for the regulatory process in Europe. And we hope that we can get an approval for the prefilled syringe and that it can be launched during the course of next year. And moving on to XB003, our biosimilar candidate to Cimzia. Um, here, as you might recall, we regained the full rights to this program from Bayer at the beginning of August this year. Um, and we have since then been running an active out-licensing process trying to identify a new suitable commercialization partner. Um, and that is moving along, um, and supported by an advisory firm specialized in these kinds of processes, and we have received the first non-binding proposals for such arrangements. Due diligence is ongoing by several different potential counterparties. And we are optimistic in being able to finalize this process and identify a suitable new commercialization partner for this program. Um, I think we also have made quite significant progress in the development. We have successfully scaled up the production process on the drug substance side, which we were very happy with. And we've confirmed analytical similarity versus the reference product at scale. So, the product is getting ready for the clinical phase, and we are planning to have scientific advice meetings with both EMA and FDA in the near future to discuss and align on a suitable clinical development plan for this program. And then we come to Xdivane, our biosimilar candidate to Opdivo. Here, we have also successfully scaled up the drug substance process and confirmed analytical similarity versus the reference product at what is going to be the clinical and commercial scale on the drug substance side. So we're very pleased with that. We have also had interactions with both the EMA and FDA, and we have reached alignment and acceptance on a clinical development plan, which is streamlined compared to the guidelines for biosimilar development, and we are planning a single pivotal trial. And in that streamlined approach, we were able to significantly reduce the envisioned development budget or clinical budget, which we're very happy with and significantly improves the prospects when it comes to identifying and securing a suitable commercialization partner for this program. And in that process, we are also making quite some progress. We have entered into the agreement negotiation phase, and we are hopeful that in the near term future, we will be able to finalize an agreement with a commercialization partner for this program. This will allow us to initiate the clinical trial during the course of the next year together with a future partner. And so that's a brief update where we're at from an operational perspective. So with that said, I'm probably going to hand over to Anette to go through the highlights on the financials.